News Related to Chronic Granulomatous Disease

Related coverage linked through entity extraction aliases.

Prime Medicine Upgraded to Buy as Gene Editing Pipeline Advances

Jul 15, 2026

Prime Medicine receives a Buy upgrade from H.C. Wainwright after New Zealand clears its first in vivo prime editing trial for Wilson's disease. The FDA also granted RMAT designation to its CGD therapy PM359. Jacob Funds and ARK Investment have recently added to their positions in the gene-editing company.

CRISPR Market Projected to Grow 24.1% as Companies Hit Milestones, Launch New Technologies

Feb 24, 2026

The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.